Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab and S1 Consolidation After CCRT in Esophageal Squamous Cell Carcinoma
NCT06422858Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- May 2024
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-Free Survival at 1 year. Started May 2024; status: recruiting.
02
Drugs
serplulimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06422858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06422858.